Summary
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.
This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Official Title
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
Keywords
Solid Tumor, Adult, Gastric (gastroesophageal cancer), Advanced Solid Tumor, Colorectal cancer, Cancer, Metastatic Solid Tumor, Combination Therapy, CD39, Adenosine Pathway, Immunotherapy Immuno-oncology, PD-1 Checkpoint Inhibitor, Docetaxel, Budigalimab, ABBV-181, TTX-030, Non-small cell lung cancer, Urothelial cell cancer, Pancreatic cancer, Pembrolizumab, Keytruda, Bladder cancer, Gemcitabine, Nab-paclitaxel, Neoplasms, Paclitaxel, Albumin-Bound Paclitaxel, TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
